EQT Private Equity agreed to acquire Qiagen for about €10.8 billion (roughly $12.1 billion), taking the life-sciences tools and diagnostics workflow provider private. The transaction values Qiagen at approximately $12.1 billion including net debt and follows years of takeover interest and strategic review deliberations. Qiagen’s boards concluded that moving under private ownership offers the best path for the next growth phase, citing flexibility to invest long term and improve prospects compared with available alternatives. EQT said it plans to use ownership to accelerate investment behind priorities while keeping Qiagen operating under its current brand until deal close. Deal terms include an all-cash takeover offer and a structure with co-investor stakes held through Luxinva and CPP Investments. The agreement also specifies conditions tied to shareholder approval thresholds and future implementation steps. For biotech stakeholders using Qiagen workflows, the deal outcome is likely to be watched for any changes in product strategy, customer support, and long-term R&D cadence under a private ownership model.